Artmış serum leptin konsantrasyonu hepatit C virüsü ile enfekte hastalarda steatozla ilişkilidir

Öz

Giriş ve Amaç: Hepatit C virüsü enfeksiyonunda steatoza yol açan mekanizma karmaşıktır. Bizim çalışmamızın amacı hepatit C virüsü ile ilgili steatozda adipositokinlerin rolünü araştırmaktır. Gereç & Yöntem: Tedavi edilmemiş genotip 1 kronik hepatit C virüslü 65 hasta adipositokinler, beden kitle indeksi, yaş, ve insulin direncinin karaciğer yağlanması ndaki etkilerini değerlendirmek için çalışmaya alındı. Bulgular: Yağlanma 31 (%47.7) hastada gözlendi. Fibroza göre adiponektin ve leptin gruplandırıldığında, adiponektin ve leptin arasında bir fark gözlemlemedik (p sırasıyla 0.597 ve 0.159). Leptin için anlamlı bir fark (p=0.021) varken, steatozlu hastalarda adiponektin düzeyleri arasında bir fark saptamadık (p=0.674). Sonuç: Hiperleptinemi kronik hepatit C virüslü hastalarda steatozun gelişimiyle ilişkilidir.

Anahtar Kelimeler

• Adiponektin, fibroz, hepatit C virüsü, insulin direnci, leptin, steatoz

Increased serum leptin concentration is related to steatosis in hepatitis C virus-infected patients

Öz

Background and Aims: The mechanism that leads to steatosis in hepatitis C virus infection is complex. The aim of our study was to search the role of adipocytokines in hepatitis C virus-related steatosis. Materials and Methods: Sixty-five untreated genotype 1 chronic hepatitis C virus patients were included in the study to evaluate the effects of adipocytokines, body mass index, age, and insulin resistance on hepatic steatosis. Results: Steatosis was observed in 31 patients (47.7%). When adiponectin and leptin were grouped according to fibrosis, we did not determine a difference between adiponectin and leptin (p values 0.597 and 0.159, respectively). We did not determine a difference in adiponectin levels in patients with different degrees of steatosis (p=0.674), while there was a significant difference for leptin (p=0.021). Conclusions: Hyperleptinemia is related to the development of steatosis in patients with chronic hepatitis C virus.

Anahtar Kelimeler

• Adiponectin, fibrosis, hepatitis C virus, insulin resistance, leptin, steatosis

Kaynakça

1. Lonardo A, Adinolfi LE, Loria P, et al. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004;126:586-97.
2. Hourigan LF, Macdonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999;29:1215-9.
3. Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-64.
4. Ohata K, Hamasaki K, Toriyama K, et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003;97:3036-43.
5. Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genome 3. J Hepatol 2000;33:106-15.
6. Monto A, Alonzo J, Watson JJ, et al. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002;36:729-36.
7. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000;11:327-32.
8. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89:2548-56.

9. Giannini E, Ceppa P, Botta F, et al. Leptin has no role in determining severity of steatosis and fibrosis in patients with chronic hepatitis C. Am J Gastroenterol 2000;9:3211-7.
10. Romero-Gomez M, Castellano-Megias VM, Grande L, et al. Serum leptin levels correlate with hepatic steatosis in chronic hepatitis C. Am J Gastroenterol 2003;98:1135-41.
11. Lopez-Bermejo A, Botas P, Funahashi T, et al. Adiponectin, hepatocellular dysfunction and insulin sensitivity. Clin Endocrinol (Oxf) 2004;60:256-63.
12. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
13. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
14. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
15. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991;13:372-4.
16. Kleiner DE, Brunt EM, Van Natta M, et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.
17. Gear EB, Shen W. Gender differences in insulin resistance, body composition, and energy balance. Gend Med 2009;6(Suppl 1):6075.
18. Klaus S. Adipose tissue as a regulator of energy balance. Curr Drug Targets 2004;5:241-50.
19. Campfield LA, Smith FJ, Guisez Y, et al. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 1995;269:546-9.
20. Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to Cq1, produced exclusively in adipocytes. J Biol Chem 1995;270:26746-9.
21. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996;271:10697-703.
22. Maeda K, Okubo K, Shimomura I, et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adipose most abundant gene transcript 1). Biochem Biophys Res Commun 1996;221:286-96.
23. Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-·, in vivo. J Clin Endocrinol Metab 1997;82:4196-200.
24. Kern PA, Saghizadeh M, Ong JM, et al. The expression of tumour necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995;95:2111-9.
25. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307-12.
26. Wiman B, Chmielewska J, Ranby M. Inactivation of tissue plasminogen activator in plasma. Demonstration of a complex with a new rapid inhibitor. J Biol Chem 1984;259:3644-7.
27. Cook KS, Groves DL, Min HY, Spiegelman BM. A developmentally regulated mRNA from 3T3 adipocytes encodes a novel serine protease homologue. Proc Natl Acad Sci U S A 1985;82:6480-4.
28. Maslowska M, Scantlebury T, Germinario R, Cianflone K. Acute in vitro production of acylation stimulating protein in differentiated human adipocytes. J Lipid Res 1997;38:1-11.
29. Bruun JM, Pedersen SB, Richelsen B. Regulation of interleukin 8 production and gene expression in human adipose tissue in vitro. J Clin Endocrinol Metab 2001;86:1267-73.
30. Manne J, Argeson AC, Siracusa LD. Mechanisms for the pleiotropic effects of the agouti gene. Proc Natl Acad Sci U S A 1995;92:4721-4.
31. Samad F, Yamamoto K, Pandey M, Loskutoff DJ. Elevated expression of transforming growth factor-‚ in adipose tissue from obese mice. Mol Med 1997;3:37-48.
32. Jones BH, Standridge MK, Taylor JW, Moustaid N. Angiotensinogen gene expression in adipose tissue: analysis of obese models and hormonal and nutritional control. Am J Physiol 1997;273:R236-42.
33. Heid HW, Moll R, Schwetlick I, et al. Adipophilin is a specific marker of lipid accumulation in diverse cell types and diseases. Cell Tissue Res 1998;294:309-21.
34. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004;25:4-7.
35. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19:972-8.
36. Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004;44:6-11.
37. Festa A, Hanley AJ, Tracy RP, et al. Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation 2003;108:1822-30.
38. Ziccardi P, Nappo F, Giugliano G, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002;105:804-9.
39. Liu ZW, Zhang N, Han QY, et al. Correlation of serum leptin levels with anthropometric and metabolic parameters and biochemical liver function in Chinese patients with chronic hepatitis C virus infection. World J Gastroenterol 2005;11:3357-62.
40. Piche T, Vandenbos F, Abakar-Mahamat A, et al. The severity of liver fibrosis is associated with high leptin levels in chronic hepatitis C. J Viral Hepat 2004;11:91-6.
41. Crespo J, Rivero M, Fabrega E, et al. Plasma leptin and TNF-alpha levels in chronic hepatitis C patients and their relationship to hepatic fibrosis. Dig Dis Sci 2002;47:1604-10.
42. Giannini E, Ceppa P, Botta F, et al. Leptin has no role in determining severity of steatosis and fibrosis in patients with chronic hepatitis C. Am J Gastroenterol 2000;95:3211-7.
43. Muzzi A, Leandro G, Rubbia-Brandt L, et al. Swiss Hepatitis C Cohort Study. Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol 2005;42:41-6.
44. Gordon A, McLean CA, Pedersen JS, et al. Hepatic steatosis in chronic hepatitis B and C: predictors, distribution and effect on fibrosis. J Hepatol 2005;43:38-44.
45. Petit JM, Minello A, Jooste V, et al. Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients. J Clin Endocrinol Metab 2005;90:2240-3.
46. Wang AY, Hickman IJ, Richards AA, et al. High molecular weight adiponectin correlates with insulin sensitivity in patients with hepatitis C genotype 3, but not genotype 1 infection. Am J Gastroenterol 2005;100:2717-23.
47. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005;128: 636-41.
48. Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology 2005;42:5-13.
49. Sato S, Furuta K, Mishiro T, et al. Serum adiponectin concentration in patients with hepatitis C virus. J Clin Gastroenterol 2005;39: 744-5.
50. Liu CJ, Chen PJ, Jeng YM, et al. Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. J Hepatol 2005;43:235-42.
51. Jonsson JR, Moschen AR, Hickman IJ, et al. Adiponectin and its receptors in patients with chronic hepatitis C. J Hepatol 2005;43:929-36. 1